Innate's Lirilumab In Limbo After Phase II Combo Failure

Bristol-Myers Squibb and Innate Pharma's anti-KIR monoclonal antibody lirilumab has failed to show efficacy in a combination trial with Opdivo in head and neck cancer – further development of the doublet treatment in solid tumors now seems unlikely.